Enhanced Outpatient Symptom Management to Reduce Acute Care Visits Due to Chemotherapy-Related Adverse Events

Summary

This clinical trial studies if enhanced outpatient symptom management with telemedicine and remote monitoring can help reduce acute care visit due to chemotherapy-related adverse events. Receiving telemedicine and remote monitoring may help patients have better outcomes (such as fewer avoidable emergency room visits and hospitalizations, better quality of life, fewer symptoms, and fewer treatment delays) than patients who receive usual care.

Conditions

• Clinical Stage IV Esophageal Adenocarcinoma AJCC v8
• Clinical Stage IV Esophageal Squamous Cell Carcinoma AJCC v8
• Clinical Stage IV Gastric Cancer AJCC v8
• Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8
• Clinical Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8
• Clinical Stage IVA Gastric Cancer AJCC v8
• Clinical Stage IVB Esophageal Adenocarcinoma AJCC v8
• Clinical Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8
• Clinical Stage IVB Gastric Cancer AJCC v8
• Metastatic Colon Carcinoma
• Metastatic Esophageal Carcinoma
• Metastatic Gastric Carcinoma
• Metastatic Liver Carcinoma
• Metastatic Malignant Digestive System Neoplasm
• Metastatic Malignant Small Intestinal Neoplasm
• Metastatic Malignant Thoracic Neoplasm
• Metastatic Pancreatic Carcinoma
• Metastatic Rectal Carcinoma
• Pathologic Stage IV Esophageal Adenocarcinoma AJCC v8
• Pathologic Stage IV Esophageal Squamous Cell Carcinoma AJCC v8
• Pathologic Stage IV Gastric Cancer AJCC v8
• Pathologic Stage IVA Esophageal Adenocarcinoma AJCC v8
• Pathologic Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8
• Pathologic Stage IVB Esophageal Adenocarcinoma AJCC v8
• Pathologic Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8
• Postneoadjuvant Therapy Stage IV Esophageal Adenocarcinoma AJCC v8
• Postneoadjuvant Therapy Stage IV Esophageal Squamous Cell Carcinoma AJCC v8
• Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8
• Postneoadjuvant Therapy Stage IVA Esophageal Adenocarcinoma AJCC v8
• Postneoadjuvant Therapy Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8
• Postneoadjuvant Therapy Stage IVB Esophageal Adenocarcinoma AJCC v8
• Postneoadjuvant Therapy Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8
• Stage IV Colon Cancer AJCC v8
• Stage IV Hepatocellular Carcinoma AJCC v8
• Stage IV Pancreatic Cancer AJCC v8
• Stage IV Rectal Cancer AJCC v8
• Stage IV Small Intestinal, Esophageal, Colorectal, Mesenteric, and Peritoneal Gastrointestinal Stromal Tumor AJCC v8
• Stage IVA Colon Cancer AJCC v8
• Stage IVA Hepatocellular Carcinoma AJCC v8
• Stage IVA Rectal Cancer AJCC v8
• Stage IVB Colon Cancer AJCC v8
• Stage IVB Hepatocellular Carcinoma AJCC v8
• Stage IVB Rectal Cancer AJCC v8
• Stage IVC Colon Cancer AJCC v8
• Stage IVC Rectal Cancer AJCC v8

Interventions

OTHER

Best Practice

Receive standard of care telemedicine

PROCEDURE

Patient Monitoring

Undergo remote monitoring

OTHER

Questionnaire Administration

Ancillary studies

Sponsors & Collaborators

• M.D. Anderson Cancer Center

  lead OTHER

Principal Investigators

• Ryan W Huey, MD · M.D. Anderson Cancer Center

Study Design

Allocation

RANDOMIZED

Purpose

HEALTH_SERVICES_RESEARCH

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2021-05-12

Primary Completion

2026-01-31

Completion

2026-01-31

Countries

• United States

Study Locations